Endocyte, which is developing EC145 (entering Phase III) for the treatment of ovarian cancer, will see its quiet period end on Tuesday, March 15. On February 3, the company raised $75 million by offering 12.5 million shares at $6, below the range of $13 to $15. RBC Capital Markets and Leerink Swann acted as lead managers on the deal.
